Markus Warmuth, H3 Biomedicine, to present at Genomic & Proteomic Drug Discovery, May 29-31, Boston Markus Warmuth, CEO of H3 Biomedicine, will give the presentation entitled “The Next Challenge – Translating the Cancer Genome into Impactful Drugs” at the 2nd Genomic & Proteomic Drug Discovery Confe
BigNews.Biz - Apr 23,2012 - Markus Warmuth, CEO of H3 Biomedicine, will give the presentation entitled “The Next Challenge – Translating the Cancer Genome into Impactful Drugs” at the 2nd Genomic & Proteomic Drug Discovery Conference on May 29-31 in Boston, MA.
Human Cancer evolves through a series of genetic and epigenetic events that allow a normal cell to become transforming and spread to distant organs. The past few years have seen a dramatic change in our understanding of the genetic basis of human cancer, mostly driven by the advances made in next generation sequencing technologies. Rapid and cost effective analysis of cancer genomes has started to not only bring new therapeutic targets to the surface, but also holds great promise in translating genetically target drugs and personalized medicines into the clinic. However, there are still many obstacles to overcome. As cancer genomic information increases on an exponential scale it has become clear that cancer genomes are complex, polyclonal and heterogeneous. In many cases it will not be possible to reduce the pathogenesis of a tumor type or subtype to a single driver activated by hotspot mutations. Instead, recent data suggest that mutations are scatter along genes and in pathways, posing the challenge of finding central and druggable nodes in the system. In addition, very little validation exists for many of the pathways emerging as frequently mutated and it is unclear if these pathways elicit oncogene addiction to a degree described for classical cancer genes (K-Ras, B-Raf, mutant EGFR, translocated kinases). Therefore, despite the promise of genetically targeted drugs, robust methods and platforms need to be established to drive validation of targets and there translation into the clinic.
Dr. Markus Warmuth joined H3 Biomedicine as Chief Scientific Officer in August 2011 and became President and Chief Executive Officer on October 1, 2011. Markus brings significant experience in cancer biology, drug discovery and clinical oncology to H3. During his career as a pharmaceutical industry research executive, he has successfully built and shaped oncology research groups and portfolios.
Prior to joining H3, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site. There, he oversaw a significant part of NIBR’s global oncology drug discovery portfolio from target discovery to clinical development.
Markus studied and received his doctorate in Medicine from the Ludwig-Maximilians-University of Munich, Germany. He trained in Internal Medicine and Oncology at the University of Munich. From 1998 to 2002, he had an appointment as a principal scientist with the “Clinical Cooperation Group Signaling” at the German National Research Center of Environment and Health (GSF), where he studied the mechanism of action of and resistance to multiple small molecule kinase inhibitors in leukemia and lymphoma.
From 2002 to April 2008, Markus worked at the Genomics Institute of the Novartis Research Foundation (GNF), San Diego, where he was Director of Kinase Biology, Head of the Oncology Pharmacology Program and a member of GNF’s Research and Drug Discovery Steering Committee.
GTC’s 2nd Genomic & Proteomic Drug Discovery Conference is a
.gif)
